May 22, 2024Journal of Neurology Neurosurgery & Psychiatry

Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world

View Full Paper

Ask AI

Bookmark

Authors

ECEdoardo CaronnaUniversitat Autònoma de Barcelona VGVictor J GallardoUniversitat Autònoma de Barcelona GEGabriella EgeoVita-Salute San Raffaele University

Discussion

Member takes

Implication

Prospective multicentre study finds anti-CGRP monoclonal antibodies reduce monthly headache days in migraine patients, highlighting that lower baseline disease burden improves treatment response.

Key Points

Early treatment with anti-CGRP monoclonal antibodies significantly enhances response rates, whereas higher baseline headache frequency reduces therapeutic success in migraine prevention.
At six months, 56.5% of individuals achieved a good response, while 26.7% showed an excellent reduction of monthly headache days under anti-CGRP monoclonal antibodies therapy.
A prospective multicentre study using generalised mixed-effect regression models highlights that timely intervention before severe disability develops optimizes clinical outcomes.

Cite This Study

Caronna et al. (2024) studied this question.

synapsesocial.com/papers/68e68d03b6db64358761527e https://doi.org/10.1136/jnnp-2023-333295

View Full Paper

Ask AI

Bookmark

Implication

Prospective multicentre study finds anti-CGRP monoclonal antibodies reduce monthly headache days in migraine patients, highlighting that lower baseline disease burden improves treatment response.

Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world

Discussion

Member takes

Implication

Key Points

Cite This Study

Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider